Alveolar lung disease

Last updated
Alveolar lung disease
Alveolus diagram.svg
Alveolus
Specialty Pulmonology

Alveolar lung diseases, are a group of diseases that mainly affect the alveoli of the lungs. [1]

Contents

Causes

Alveoli are the functional units of the lungs. Alveolar lung diseases are classified as processes that affect these units that ultimately lead to issues with ventilation. There are a number of different causes of insult to the alveoli including build up of fluid, hemorrhage, infection, malignancy and build up of protein and mineral deposits.

Conditions classified under alveolar lung disease include pulmonary edema (cardiogenic or non-cardiogenic), pneumonia (bacterial or viral), bronchoalveolar carcinoma, pulmonary hemorrhage, alveolar proteinosis and amyloidosis, and alveolar microlithiasis.

Alveolar lung disease may be divided into acute or chronic. Causes of acute alveolar lung disease include pulmonary edema (cardiogenic or neurogenic), pneumonia (bacterial or viral), systemic lupus erythematosus, [2] bleeding in the lungs (e.g., Goodpasture syndrome), [3] idiopathic pulmonary hemosiderosis, [4] and granulomatosis with polyangiitis.

Chronic alveolar lung disease can be caused by pulmonary alveolar proteinosis, [5] alveolar cell carcinoma, mineral oil pneumonia, sarcoidosis (alveolar form), lymphoma, tuberculosis, metastases, or desquamative interstitial pneumonia.

Diagnosis

Initial evaluation and Testing

Patients with alveolar lung disease may have difficulty breathing and/or a cough which may be productive of sputum or blood.

A physician will listen to the patient's lungs to help determine if there is likely a lower lung disease. Depending on the type of alveolar lung disease, the listener may hear "crackles" that indicate an excess of fluid in the lungs or an absence of lung sounds in certain regions which may indicate poor ventilation due to consolidation of pus or fibrosis. [6]

A pulse oximeter is a device that measures the amount of oxygen available in the blood. This is an important measurement in evaluation of a patient with difficulty breathing with suspected alveolar lung disease.

Imaging

Chest x-ray is the initial imaging modality of choice for evaluation of potential alveolar lung disease. Bedside ultrasound may also be utilized. The absence of radiographic evidence early on in the course of disease does not exclude alveolar disease.

Alveolar disease is visible on chest radiography as small, ill-defined nodules of homogeneous density centered on the acini or bronchioles. The nodules coalesce early in the course of disease, such that the nodules may only be seen as soft fluffy edges in the periphery. [1]

When the nodules are centered on the hilar regions, the chest x-ray may develop what is called the "butterfly," or "batwing" appearance. The nodules may also have a segmental or lobar distribution. Air alveolograms and air bronchograms can also be seen which indicate fluid in the alveoli with air in the terminal bronchioles indicating disease is alveolar. [1]

These findings appear soon after the onset of symptoms and change rapidly thereafter.

A segmental or lobar pattern may be apparent after aspiration pneumonia, atelectasis, lung contusion, localized pulmonary edema, obstructive pneumonia, pneumonia, pulmonary embolism with infarction, or tuberculosis.

Management

The two focuses of management for alveolar disease is supportive care to maintain oxygenation and ventilation to ensure that adequate oxygen is being delivered to blood, and to treat the underlying insult to the alveoli.

Supportive Care

Maintaining oxygenation and ventilation in alveolar lung disease is achieved through a number of methods. The mechanism of these treatments is primarily to provide oxygen and keep the alveoli open so that they can take up oxygen from and deliver it to the bloodstream. Ventilatory support is recognized as an essential component to treat pulmonary edema and acute respiratory distress syndrome. [7]

Non-invasive ventilation is the first step for patient's who require ventilatory support. This can take the form of oxygen delivered via nasal cannula or non-rebreather mask. Patients who require additional support may be given a high-flow nasal cannula which has an added function of providing positive pressure on the alveoli, can warm and humidify air and decrease required inspiratory effort of the patient. [8] BiPAP and CPAP can also be used as next level treatment. Finally, intubation with ventilator support can be used with positive pressure to improve ventilation and oxygenation. [9]  

In cases where methods to support the lungs to provide oxygen to the blood fail, extracorporeal membrane oxygenation, or ECMO can be considered.

Treating underlying causes

Treating underlying causes of damage to alveoli is also essential in most alveolar lung disease.  

Some more commonly seen instances of alveolar lung disease include pulmonary edema and pneumonia.

For pulmonary edema, medical treatment in addition to measures to maintain ventilation include diuretics to remove excess fluid from the lungs. Presumed bacterial pneumonia is typically treated with antibiotics.

Related Research Articles

<span class="mw-page-title-main">Meconium aspiration syndrome</span> Medical condition affecting newborn infants

Meconium aspiration syndrome (MAS) also known as neonatal aspiration of meconium is a medical condition affecting newborn infants. It describes the spectrum of disorders and pathophysiology of newborns born in meconium-stained amniotic fluid (MSAF) and have meconium within their lungs. Therefore, MAS has a wide range of severity depending on what conditions and complications develop after parturition. Furthermore, the pathophysiology of MAS is multifactorial and extremely complex which is why it is the leading cause of morbidity and mortality in term infants.

<span class="mw-page-title-main">Pulmonary alveolus</span> Hollow cavity found in the lungs

A pulmonary alveolus, also known as an air sac or air space, is one of millions of hollow, distensible cup-shaped cavities in the lungs where pulmonary gas exchange takes place. Oxygen is exchanged for carbon dioxide at the blood–air barrier between the alveolar air and the pulmonary capillary. Alveoli make up the functional tissue of the mammalian lungs known as the lung parenchyma, which takes up 90 percent of the total lung volume.

<span class="mw-page-title-main">Respiratory failure</span> Inadequate gas exchange by the respiratory system

Respiratory failure results from inadequate gas exchange by the respiratory system, meaning that the arterial oxygen, carbon dioxide, or both cannot be kept at normal levels. A drop in the oxygen carried in the blood is known as hypoxemia; a rise in arterial carbon dioxide levels is called hypercapnia. Respiratory failure is classified as either Type 1 or Type 2, based on whether there is a high carbon dioxide level, and can be acute or chronic. In clinical trials, the definition of respiratory failure usually includes increased respiratory rate, abnormal blood gases, and evidence of increased work of breathing. Respiratory failure causes an altered mental status due to ischemia in the brain.

<span class="mw-page-title-main">Respiratory tract</span> Organs involved in transmission of air to and from the point where gases diffuse into tissue

The respiratory tract is the subdivision of the respiratory system involved with the process of respiration in mammals. The respiratory tract is lined with respiratory epithelium as respiratory mucosa.

<span class="mw-page-title-main">Pulmonary edema</span> Fluid accumulation in the tissue and air spaces of the lungs

Pulmonary edema, also known as pulmonary congestion, is excessive liquid accumulation in the tissue and air spaces of the lungs. It leads to impaired gas exchange and may cause hypoxemia and respiratory failure. It is due to either failure of the left ventricle of the heart to remove oxygenated blood adequately from the pulmonary circulation, or an injury to the lung tissue directly or blood vessels of the lung.

<span class="mw-page-title-main">Acute respiratory distress syndrome</span> Human disease

Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. Symptoms include shortness of breath (dyspnea), rapid breathing (tachypnea), and bluish skin coloration (cyanosis). For those who survive, a decreased quality of life is common.

<span class="mw-page-title-main">Pulmonary alveolar proteinosis</span> Medical condition

Pulmonary alveolar proteinosis (PAP) is a rare lung disorder characterized by an abnormal accumulation of surfactant-derived lipoprotein compounds within the alveoli of the lung. The accumulated substances interfere with the normal gas exchange and expansion of the lungs, ultimately leading to difficulty breathing and a predisposition to developing lung infections. The causes of PAP may be grouped into primary, secondary, and congenital causes, although the most common cause is a primary autoimmune condition in an individual.

<span class="mw-page-title-main">Atelectasis</span> Partial collapse of a lung causing reduced gas exchange

Atelectasis is the partial collapse or closure of a lung resulting in reduced or absent gas exchange. It is usually unilateral, affecting part or all of one lung. It is a condition where the alveoli are deflated down to little or no volume, as distinct from pulmonary consolidation, in which they are filled with liquid. It is often referred to informally as a collapsed lung, although more accurately it usually involves only a partial collapse, and that ambiguous term is also informally used for a fully collapsed lung caused by a pneumothorax.

<span class="mw-page-title-main">Interstitial lung disease</span> Group of diseases

Interstitial lung disease (ILD), or diffuse parenchymal lung disease (DPLD), is a group of respiratory diseases affecting the interstitium and space around the alveoli of the lungs. It concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, and perivascular and perilymphatic tissues. It may occur when an injury to the lungs triggers an abnormal healing response. Ordinarily, the body generates just the right amount of tissue to repair damage, but in interstitial lung disease, the repair process is disrupted, and the tissue around the air sacs (alveoli) becomes scarred and thickened. This makes it more difficult for oxygen to pass into the bloodstream. The disease presents itself with the following symptoms: shortness of breath, nonproductive coughing, fatigue, and weight loss, which tend to develop slowly, over several months. The average rate of survival for someone with this disease is between three and five years. The term ILD is used to distinguish these diseases from obstructive airways diseases.

<span class="mw-page-title-main">Pulmonary hemorrhage</span> Medical condition

Pulmonary hemorrhage is an acute bleeding from the lung, from the upper respiratory tract and the trachea, and the pulmonary alveoli. When evident clinically, the condition is usually massive. The onset of pulmonary hemorrhage is characterized by a cough productive of blood (hemoptysis) and worsening of oxygenation leading to cyanosis. Treatment should be immediate and should include tracheal suction, oxygen, positive pressure ventilation, and correction of underlying abnormalities such as disorders of coagulation. A blood transfusion may be necessary.

<span class="mw-page-title-main">Acute interstitial pneumonitis</span> Medical condition

Acute interstitial pneumonitis (also known as acute interstitial pneumoniais a rare, severe lung disease that usually affects otherwise healthy individuals. There is no known cause or cure.

<span class="mw-page-title-main">Respiratory disease</span> Disease of the respiratory system

Respiratory diseases, or lung diseases, are pathological conditions affecting the organs and tissues that make gas exchange difficult in air-breathing animals. They include conditions of the respiratory tract including the trachea, bronchi, bronchioles, alveoli, pleurae, pleural cavity, the nerves and muscles of respiration. Respiratory diseases range from mild and self-limiting, such as the common cold, influenza, and pharyngitis to life-threatening diseases such as bacterial pneumonia, pulmonary embolism, tuberculosis, acute asthma, lung cancer, and severe acute respiratory syndromes, such as COVID-19. Respiratory diseases can be classified in many different ways, including by the organ or tissue involved, by the type and pattern of associated signs and symptoms, or by the cause of the disease.

A pulmonary shunt is the passage of deoxygenated blood from the right side of the heart to the left without participation in gas exchange in the pulmonary capillaries. It is a pathological condition that results when the alveoli of parts of the lungs are perfused with blood as normal, but ventilation fails to supply the perfused region. In other words, the ventilation/perfusion ratio of those areas is zero.

Restrictive lung diseases are a category of extrapulmonary, pleural, or parenchymal respiratory diseases that restrict lung expansion, resulting in a decreased lung volume, an increased work of breathing, and inadequate ventilation and/or oxygenation. Pulmonary function test demonstrates a decrease in the forced vital capacity.

<span class="mw-page-title-main">Pulmonary contusion</span> Internal bruise of the lungs

A pulmonary contusion, also known as lung contusion, is a bruise of the lung, caused by chest trauma. As a result of damage to capillaries, blood and other fluids accumulate in the lung tissue. The excess fluid interferes with gas exchange, potentially leading to inadequate oxygen levels (hypoxia). Unlike pulmonary laceration, another type of lung injury, pulmonary contusion does not involve a cut or tear of the lung tissue.

<span class="mw-page-title-main">Diffuse alveolar damage</span> Medical condition

Diffuse alveolar damage (DAD) is a histologic term used to describe specific changes that occur to the structure of the lungs during injury or disease. Most often DAD is described in association with the early stages of acute respiratory distress syndrome (ARDS). It is important to note that DAD can be seen in situations other than ARDS (such as acute interstitial pneumonia) and that ARDS can occur without DAD.

<span class="mw-page-title-main">Ground-glass opacity</span> Radiologic sign on radiographs and computed tomography scans

Ground-glass opacity (GGO) is a finding seen on chest x-ray (radiograph) or computed tomography (CT) imaging of the lungs. It is typically defined as an area of hazy opacification (x-ray) or increased attenuation (CT) due to air displacement by fluid, airway collapse, fibrosis, or a neoplastic process. When a substance other than air fills an area of the lung it increases that area's density. On both x-ray and CT, this appears more grey or hazy as opposed to the normally dark-appearing lungs. Although it can sometimes be seen in normal lungs, common pathologic causes include infections, interstitial lung disease, and pulmonary edema.

Prone ventilation, sometimes called prone positioning or proning, refers to mechanical ventilation with the patient lying face-down (prone). It improves oxygenation in most patients with acute respiratory distress syndrome (ARDS) and reduces mortality. The earliest trial investigating the benefits of prone ventilation occurred in 1976. Since that time, many meta-analyses and one randomized control trial, the PROSEVA trial, have shown an increase in patients' survival with the more severe versions of ARDS. There are many proposed mechanisms, but they are not fully delineated. The proposed utility of prone ventilation is that this position will improve lung mechanics, improve oxygenation, and increase survival. Although improved oxygenation has been shown in multiple studies, this position change's survival benefit is not as clear. Similar to the slow adoption of low tidal volume ventilation utilized in ARDS, many believe that the investigation into the benefits of prone ventilation will likely be ongoing in the future.

<span class="mw-page-title-main">Pathophysiology of acute respiratory distress syndrome</span>

The pathophysiology of acute respiratory distress syndrome involves fluid accumulation in the lungs not explained by heart failure. It is typically provoked by an acute injury to the lungs that results in flooding of the lungs' microscopic air sacs responsible for the exchange of gases such as oxygen and carbon dioxide with capillaries in the lungs. Additional common findings in ARDS include partial collapse of the lungs (atelectasis) and low levels of oxygen in the blood (hypoxemia). The clinical syndrome is associated with pathological findings including pneumonia, eosinophilic pneumonia, cryptogenic organizing pneumonia, acute fibrinous organizing pneumonia, and diffuse alveolar damage (DAD). Of these, the pathology most commonly associated with ARDS is DAD, which is characterized by a diffuse inflammation of lung tissue. The triggering insult to the tissue usually results in an initial release of chemical signals and other inflammatory mediators secreted by local epithelial and endothelial cells.

<span class="mw-page-title-main">Ventilation–perfusion coupling</span> Relationship between respiratory and cardiovascular processes

Ventilation-perfusion coupling is the relationship between ventilation and perfusion processes, which take place in the respiratory system and the cardiovascular system. Ventilation is the movement of gas during breathing, and perfusion is the process of pulmonary blood circulation, which delivers oxygen to body tissues. Anatomically, the lung structure, alveolar organization, and alveolar capillaries contribute to the physiological mechanism of ventilation and perfusion. Ventilation-perfusion coupling maintains a constant ventilation/perfusion ratio near 0.8 on average, while the regional variation exists within the lungs due to gravity. When the ratio gets above or below 0.8, it is considered abnormal ventilation-perfusion coupling, also known as a ventilation–perfusion mismatch. Lung diseases, cardiac shunts, and smoking can cause a ventilation-perfusion mismatch that results in significant symptoms and diseases, which can be treated through treatments like bronchodilators and oxygen therapy.

References

  1. 1 2 3 Al-Tubaikh, JA (2010). "Chapter 3.2 Alveolar lung diseases". Internal Medicine . Springer. p.  113. ISBN   978-3642037085.
  2. Amarnani, Raj; Yeoh, Su-Ann; Denneny, Emma K.; Wincup, Chris (2021-01-18). "Lupus and the Lungs: The Assessment and Management of Pulmonary Manifestations of Systemic Lupus Erythematosus". Frontiers in Medicine. 7: 610257. doi: 10.3389/fmed.2020.610257 . ISSN   2296-858X. PMC   7847931 . PMID   33537331.
  3. Marques, C.; Plaisier, E.; Cacoub, P.; Cadranel, J.; Saadoun, D. (2020-01-01). "Mise au point sur la maladie des anticorps anti-membrane basale glomérulaire ou syndrome de Goodpasture". La Revue de Médecine Interne (in French). 41 (1): 14–20. doi: 10.1016/j.revmed.2019.10.338 . ISSN   0248-8663. PMID   31776042. S2CID   241253029.
  4. Saha, Biplab K. (2021-01-01). "Idiopathic pulmonary hemosiderosis: A state of the art review". Respiratory Medicine. 176: 106234. doi: 10.1016/j.rmed.2020.106234 . ISSN   0954-6111. PMID   33246295. S2CID   227191691.
  5. Jouneau, Stéphane; Ménard, Cédric; Lederlin, Mathieu (2020-05-03). "Pulmonary alveolar proteinosis". Respirology. 25 (8): 816–826. doi:10.1111/resp.13831. ISSN   1323-7799. PMID   32363736. S2CID   218492929.
  6. Reyes, Felix M.; Le, Jacqueline K. (2020), "Lung Exam", StatPearls, StatPearls Publishing, PMID   29083650 , retrieved 2020-04-19
  7. Fan, Eddy; Brodie, Daniel; Slutsky, Arthur S. (2018-02-20). "Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment". JAMA. 319 (7): 698–710. doi:10.1001/jama.2017.21907. ISSN   0098-7484. PMID   29466596. S2CID   3451752.
  8. Lodeserto, Frank J.; Lettich, Thomas M.; Rezaie, Salim R. (2018-11-26). "High-flow Nasal Cannula: Mechanisms of Action and Adult and Pediatric Indications". Cureus. 10 (11): e3639. doi: 10.7759/cureus.3639 . ISSN   2168-8184. PMC   6358040 . PMID   30740281.
  9. Bello, Giuseppe; De Santis, Paolo; Antonelli, Massimo (September 2018). "Non-invasive ventilation in cardiogenic pulmonary edema". Annals of Translational Medicine. 6 (18): 355. doi: 10.21037/atm.2018.04.39 . ISSN   2305-5839. PMC   6186545 . PMID   30370282.